James Eric Strong

Dr. James Eric Strong

Public Health Agency of Canada, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
BWBryce Warner
Bryce Warner
LKLevi Klassen
Levi Klassen
ASAngela Sloan
Angela Sloan
YDYvon Deschambault
Yvon Deschambault
GSGeoff Soule
Geoff Soule
DSDavid Safronetz
David Safronetz
The recent emergence of the monkeypox virus (MPXV) in non-endemic countries has been designated a Public Health Emergency of International Concern by the World Health Organization. There are currently no approved treatments for MPXV infection in the United States or Canada. The antiviral drug tecovirimat (commonly called TPOXX), previously approved for smallpox treatment, is currently being deployed for treatment of MPXV infections where available based on previously accrued data. We tested the efficacy of TPOXX both in vitro and in vivo against a clade 2 Canadian 2022 isolate of MPXV isolated during the current outbreak. TPOXX prevented MPXV replication in vitro with an effective concentration in the nanomolar range. To evaluate TPOXX efficacy in vivo, we first characterized the CAST/EiJ mouse model with the same 2022 Canadian isolate. Unlike previous descriptions of this model, the Canadian isolate was not lethal in CAST/EiJ mice, although it replicated efficiently in the respiratory tract after intranasal infection. Subsequent experiments demonstrated that daily oral TPOXX treatment markedly reduced viral titers in the tissues 1 and 2 weeks after infection. Our data indicate that TPOXX is highly effective against currently circulating MPXV strains and could be an important contributor to curbing the ongoing outbreak.

14 April 2015 in Viruses
Verified
Journal Article
Open access
PDF file
BCBradley W. M. Cook
Bradley W. M. Cook
TCTodd Cutts
Todd Cutts
ANAidan M. Nikiforuk
Aidan M. Nikiforuk
PPPhilip Guillaume Poliquin
Philip Guillaume Poliquin
DCDeborah Court
Deborah Court
STSteven Theriault
Steven Theriault
Background: The current disease outbreak caused by the Ebola virus Makona variant (EBOV/Mak) has led to unprecedented morbidity and lethality given its geographic reach and sustained transmission. Sodium hypochlorite and ethanol are well-accepted decontamination agents, however little published evidence supports the selection of appropriate concentrations and contact times. The present study addresses the environmental robustness of EBOV/Mak and evaluates the effectiveness of sodium hypochlorite and ethanol as disinfectants. Methods: EBOV/Mak was suspended in a simulated organic soil load and dried onto surfaces. Viability was measured at 1 hour, 24 hours, 72 hours, and 192 hours. For the evaluation of disinfectants, EBOV/Mak in a simulated organic soil was dried onto stainless steel carriers and disinfected with 0.01% (v/v), 0.1% (v/v), 0.5% (v/v) and 1% (v/v) sodium hypochlorite solutions or 67% (v/v) ethanol at contact times of 1, 5 or 10 minutes. Results: EBOV/Mak persisted longer on steel and plastic surfaces (192 hours) than cotton (<24 hours). Dilute sodium hypochlorite (0.01% and 0.1%) showed little antiviral action, whereas 0.5% and 1% sodium hypochlorite solutions demonstrated recoverable virus at one minute but sterilized surfaces in five minutes. Disinfection with 67% ethanol did not fully clear infectious virions from 3/9 carriers at 1 minute but sterilized all carriers at 5 and 10 minutes. Conclusions: Sodium hypochlorite and ethanol effectively decontaminate EBOV/Mak suspended in a simulated organic load; however, selection of concentration and contact time proves critical.

16 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKAnand Kumar
Anand Kumar
SKSamantha B. Kasloff
Samantha B. Kasloff
ALAnders Leung
Anders Leung
TCTodd Cutts
Todd Cutts
JSJames Eric Strong
James Eric Strong
JKJay Krishnan
Jay Krishnan
The response to the COVID-19 epidemic is generating severe shortages of personal protective equipment around the world. In particular, the supply of N95 respirator masks has become severely depleted, with supplies having to be rationed and health care workers having to use masks for prolonged periods in many countries. We sought to test the ability of 7 different decontamination methods: autoclave treatment, ethylene oxide gassing (ETO), low temperature hydrogen peroxide gas plasma (LT-HPGP) treatment, vaporous hydrogen peroxide (VHP) exposure, peracetic acid dry fogging (PAF), ultraviolet C irradiation (UVCI) and moist heat (MH) treatment to decontaminate a variety of different N95 masks following experimental contamination with SARS-CoV-2 or vesicular stomatitis virus as a surrogate. In addition, we sought to determine whether masks would tolerate repeated cycles of decontamination while maintaining structural and functional integrity. All methods except for UVCI were effective in total elimination of viable virus from treated masks. We found that all respirator masks tolerated at least one cycle of all treatment modalities without structural or functional deterioration as assessed by fit testing; filtration efficiency testing results were mostly similar except that a single cycle of LT-HPGP was associated with failures in 3 of 6 masks assessed. VHP, PAF, UVCI, and MH were associated with preserved mask integrity to a minimum of 10 cycles by both fit and filtration testing. A similar result was shown with ethylene oxide gassing to the maximum 3 cycles tested. Pleated, layered non-woven fabric N95 masks retained integrity in fit testing for at least 10 cycles of autoclaving but the molded N95 masks failed after 1 cycle; filtration testing however was intact to 5 cycles for all masks. The successful application of autoclaving for layered, pleated masks may be of particular use to institutions globally due to the virtually universal accessibility of autoclaves in health care settings. Given the ability to modify widely available heating cabinets on hospital wards in well-resourced settings, the application of moist heat may allow local processing of N95 masks.

8 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AKAnand Kumar
Anand Kumar
SKSamantha B. Kasloff
Samantha B. Kasloff
ALAnders Leung
Anders Leung
TCTodd Cutts
Todd Cutts
JSJames Eric Strong
James Eric Strong
JKJay Krishnan
Jay Krishnan
The response to the COVID-19 epidemic is generating severe shortages of personal protective equipment around the world. In particular, the supply of N95 respirator masks has become severely depleted, with supplies having to be rationed and health care workers having to use masks for prolonged periods in many countries. We sought to test the ability of 5 different decontamination methods: autoclave treatment, ethylene oxide gassing, low temperature hydrogen peroxide gas plasma treatment, vaporous hydrogen peroxide exposure and peracetic acid dry fogging to decontaminate a variety of different N95 masks of experimental contamination with SARS-CoV-2 or Vesicular stomatitis virus as a surrogate. In addition, we sought to determine whether masks would tolerate repeated cycles of decontamination while maintaining structural and functional integrity. We found that one cycle of treatment with all modalities was effective in decontamination and was associated with no structural or functional deterioration. Vaporous hydrogen peroxide, peracetic acid dry fogging and autoclave treatments were associated with no loss of structural or functional integrity to a minimum of 10 cycles for the mask models tested. The molded N95 masks however tolerated only 1 cycle of autoclaving. The successful application of autoclaving for layered fabric, pleated masks may be of particular use to institutions globally due to the virtually universal accessibility of autoclaves in health care settings.

1 November 2020 in Journal of Virological Methods
Verified
Journal Article
Open access
LGLauren Garnett
Lauren Garnett
ABAlexander Bello
Alexander Bello
KTKaylie N. Tran
Kaylie N. Tran
JAJonathan Audet
Jonathan Audet
ALAnders Leung
Anders Leung
JSJames Eric Strong
James Eric Strong
• High demand for diagnostic testing for COVID-19 has depleted commercially available consumables for diagnostic testing. • Alternative swabs that are not approved for Nasopharyngeal sampling work well for COVID-19 diagnostics. • Alternative fluids that are readily available in hospital settings can function as alternatives to Viral Transport Media. • No meaningful difference in viral yield from different swabs and most transport mediums for the collection and detection of SARS-CoV-2, indicating swab and medium alternatives could be used if supplies run out.

10 March 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
HLHongzhao Li
Hongzhao Li
ABAlexander J. Bello
Alexander J. Bello
GSGreg Smith
Greg Smith
DKDominic M. S. Kielich
Dominic M. S. Kielich
JSJames Eric Strong
James Eric Strong
BPBrad S. Pickering
Brad S. Pickering
CRISPR (clustered regularly interspaced short palindromic repeats), an ancient defense mechanism used by prokaryotes to cleave nucleic acids from invading viruses and plasmids, is currently being harnessed by researchers worldwide to develop new point-of-need diagnostics. In CRISPR diagnostics, a CRISPR RNA (crRNA) containing a “spacer” sequence that specifically complements with the target nucleic acid sequence guides the activation of a CRISPR effector protein (Cas13a, Cas12a or Cas12b), leading to collateral cleavage of RNA or DNA reporters and enormous signal amplification. CRISPR function can be disrupted by some types of sequence mismatches between the spacer and target, according to previous studies. This poses a potential challenge in the detection of variable targets such as RNA viruses with a high degree of sequence diversity, since mismatches can result from target variations. To cover viral diversity, we propose in this study that during crRNA synthesis mixed nucleotide types (degenerate sequences) can be introduced into the spacer sequence positions corresponding to viral sequence variations. We test this crRNA design strategy in the context of the Cas13a-based SHERLOCK (specific high-sensitivity enzymatic reporter unlocking) technology for detection of Crimean–Congo hemorrhagic fever virus (CCHFV), a biosafety level 4 pathogen with wide geographic distribution and broad sequence variability. The degenerate-sequence CRISPR diagnostic proves functional, sensitive, specific and rapid. It detects within 30–40 minutes 1 copy/μl of viral RNA from CCHFV strains representing all clades, and from more recently identified strains with new mutations in the CRISPR target region. Also importantly, it shows no cross-reactivity with a variety of CCHFV-related viruses. This proof-of-concept study demonstrates that the degenerate sequence-based CRISPR diagnostic is a promising tool of choice for effective detection of highly variable viral pathogens.